The potential use of Cannabidiol in Mycobacterium tuberculosis infection

MARTINENA CAMILA; CORLETO MERLINA; MARTIN CANDELA; DONNOLI L; ZUAZO ROCIO; BAZAN ANA; VITTI AGUSTIN; MORELLI, MARÍA PAULA; MUSELLA, R; CIALLELLA, L; DE CASADO, GRACIELA C; PALMERO, DJ; AMIANO, N; GARCIA, VE; MAFFIA, P; TATEOSIAN, NANCY L.

Congreso; . LXX Reunión Anual de la Sociedad Argentina de Inmunología (SAI),; 2022

Cannabidiol (CBD), the main non-psychoactive ingredient of the cannabis plant, is one of more than 100 cannabinoids that can be extracted from the Cannabis sativa L., many of which have been shown to be biologically active. Besides the scientific research, the societal acceptance of CBD oil for medical application has increased in recent years. However, in spite of the increasing research, all of CBD biological effects are not completely understood. The purpose of this work was to investigate the antimicrobial and immunomodulatory effects of CBD in Mycobacterium tuberculosis (Mtb) infection. Results: First, we evaluated the anti-mycobacterial effect of different concentrations of CBD (150μg/mL, 15μg/mL, 1.5μg/mL 0,15µg/mL and 0,015µg/mL) by colony forming units (CFU) counts after2hours and 24hours of treatment. We found that CBD treatment produced a decrease in MtbH37Rv viability in a dose dependent manner at 2hours and 24hours (ANOVA test, p